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OBJECTIVE—Insulin-resistant states, such as obesity and type
2 diabetes, contribute substantially to accelerated atherogenesis.
Null mutations of myostatin (Mstn) are associated with in-
creased muscle mass and decreased fat mass. In this study, we
determined whether Mstn disruption could prevent the develop-
ment of insulin resistance, proatherogenic dyslipidemia, and
atherogenesis.
RESEARCH DESIGN AND METHODS—C57BL/6 Ldlr/
mice were cross-bred with C57BL/6 Mstn/ mice for 10
generations to generate Mstn//Ldlr/ double-knockout mice.
The effects of high-fat/high-cholesterol diet on body composition,
plasma lipids, systemic and tissue-specific insulin sensitivity,
hepatic steatosis, as well as aortic atheromatous lesion were
characterized in Mstn//Ldlr/ mice in comparison with con-
trol Mstn//Ldlr/ mice.
RESULTS—Compared with Mstn//Ldlr/ controls, Mstn//
Ldlr/ mice were resistant to diet-induced obesity, and had
greatly improved insulin sensitivity, as indicated by 42% higher
glucose infusion rate and 90% greater muscle [3H]-2-deoxyglu-
cose uptake during hyperinsulinemic-euglycemic clamp. Mstn//
Ldlr/ mice were protected against diet-induced hepatic
steatosis and had 56% higher rate of hepatic fatty acid -
oxidation than controls. Mstn//Ldlr/ mice also had 36%
lower VLDL secretion rate and were protected against diet-
induced dyslipidemia, as indicated by 30–60% lower VLDL and
LDL cholesterol, free fatty acids, and triglycerides. Magnetic
resonance angiography and en face analyses demonstrated 41%
reduction in aortic atheromatous lesions in Ldlr/ mice with
Mstn deletion.
CONCLUSIONS—Inactivation of Mstn protects against the de-
velopment of insulin resistance, proatherogenic dyslipidemia,
and aortic atherogenesis in Ldlr/ mice. Myostatin may be a
useful target for drug development for prevention and treatment
of obesity and its associated type 2 diabetes and atherosclerosis.
Diabetes 58:1739–1748, 2009
Heart disease and diabetes rank among the mostprevalent disorders in most Western countries,and their incidence rates within the elderlypopulation are particularly high (1). Aging is
associated with decrease in muscle mass, increase in fat
mass (2), insulin resistance, and athersclerosis progres-
sion, all conditions that predispose individuals to cardio-
metabolic diseases. Therefore, adiposity, sarcopenia, and
heart disease are interrelated consequences of aging that
contribute substantially to morbidity and mortality among
older humans.
Currently, most available therapies for heart disease,
such as statins, are based on lowering of plasma cho-
lesterol. These interventions have little effect on adipos-
ity and sarcopenia. We surmised that unlike available
pharmacological therapies that are mostly targeted at
cholesterol synthesis or metabolism, novel therapeutic
strategies, such as myostatin inactivation, that directly
target muscle and fat mass accumulation may be effec-
tive in protection against obesity and its metabolic
ramifications.
Genetic disruption of myostatin, a transforming growth
factor- (TGF-) family member that functions as an
endogenous inhibitor of muscle growth (3–5), leads to
increased skeletal muscle mass and decreased fat mass in
humans, cattle, mice, and other species (6,7). Disruption
of myostatin gene has also been shown to prevent the
development of obesity (6). Inhibition of myostatin, either
directly or through overexpression of myostatin propep-
tide, an endogenous myostatin inhibitor, has also been
shown to prevent the development of obesity and insulin
resistance (6).
In this study, we show that the loss of myostatin
attenuates the development of atherogenic lipid profile
and the progression of atheromatous lesion growth in LDL
receptor–null (Ldlr/) mice, a widely used experimental
model of atherogenesis. When Ldlr/ mice, lacking the
cell-surface transmembrane receptor that recognizes apo-
lipoprotein B100 (apoB100), are fed Western-type diet,
they display hypercholesterolemia and atheromatous le-
sions resembling those observed in patients with familial
hypercholesterolemia (8). Our data show that Mstn dis-
ruption in Ldlr/ mice not only attenuates diet-induced
fat accumulation and improves whole body insulin sensi-
tivity, as has been reported recently (9,10), but it also
prevents the hepatic hypersecretion of proatherogenic
lipoprotein, protects against the development of pro-
atherogenic dyslipidemia, and reduces atherogenesis
progression.
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RESEARCH DESIGN AND METHODS
C57BL/6 mice with homozygous deletion of Ldlr (Jackson Laboratory, Bar
Harbor, ME) were cross-bred with C57BL/6 mice with homozygous deletion of
Mstn. Their offsprings were bred 10 times to generate Mstn//Ldlr/
double-knockout mice. All mice used in this study were males. Mice were
provided food and water ad libitum and maintained on a 12-h light/dark cycle.
Mice were fed normal rodent diet (TD#2018, Harland Teklad, Madison, WI)
until 4 months of age, then fed with high-fat/high-cholesterol diet (HFD)
(TD#94059, Harland Teklad). The HFD contained 15.8% w/w fat (primarily
from cocoa butter), 1.25% w/w cholesterol, 41.2% w/w carbohydrate, and 19.7%
w/w protein. Food consumption was measured using powdered HFD provided
in glass jars with perforated metal tops to prevent scattering. Study protocols
were approved by the Boston University’s Institutional Animal Care and Use
Committee.
Body composition and metabolic cage measurements. Whole body fat and
muscle mass were determined by nuclear magnetic resonance (NMR;
EchoMRI-100, Echo Medical System, Houston, TX). Visceral and subcutane-
ous fat imaging were performed using low-energy X-ray micro–computed
tomography (CT) scanner (LaTheta LCT-100A, Echo Medical System). Oxygen
consumption and respiratory exchange ratio rates were measured using
Oxymax system (Columbus Instruments, Columbus, OH) as previously
described (11).
Magnetic resonance angiography. Mice were anesthetized using 1–2% (v/v)
isoflurane and 1–2 L/min oxygen flow through an anesthesia monitoring
system (Smiths Medical PM, Waukesha, WI). Respiration was monitored by
respiration sensor pillow (SA Instruments, Stony Brook, NY). Imaging was
performed using a Bruker Avance 500 vertical bore spectrometer with 11.7 T
(Bruker, Billerica, MA). Data acquisition and reconstruction were performed
with the ParaVision 3.0.2. 3D magnetic resonance angiography (MRA) and
were obtained using the FLASH_3D_ANGIO pulse sequence (flip angle  20°,
TE/TR  2.18 ms/20 ms, FOV  15 mm  15 mm  15 mm). Four averages
were obtained in each scan.
En face detection of atheromatous lesions. Preparation of aortas and
quantification of atheromatous lesions were performed in animals after 12
weeks of HFD feeding, using procedures previously described (12). The heart
with aorta was embedded in optimal cutting temperature (OCT) (Sakura
Finetech USA, Torrance, CA), and serial 10 m-thick cytosections of aortic
root were stained with Oil Red O by the Rodent Histopathology Core at
Harvard Medical School (Boston, MA).
Measurements of plasma lipids and other metabolites. Blood glucose and
ketone concentrations were determined using Glucometer Elite XL (Bayer,
Tarrytown, NY) and Precision Xtra (Abbott Laboratories, Bedford, MA),
respectively. Plasma insulin and glucagon were measured using ultrasensitive
ELISA (Alpco, Salem, NH). For lipid analyses, fasting (food removed for 12 h)
and nonfasting (food removed for 3 h) blood samples were collected from the
retro-orbital plexus under isoflurane anesthesia. Lipid analyses were per-
formed using procedures previously described (13). Cholesterol and triglyc-
eride distribution of the lipoproteins were performed by Cardiovascular
Specialty Laboratories (Atlanta, GA) using fast-performance liquid chroma-
tography (14). Fractions 2–6 contain VLDL; fractions 7–11 contain LDL; and
fractions 14–17 contain HDL.
Glucose and insulin tolerance tests. For glucose tolerance tests, fasting
mice were given D-glucose (1 g/kg) by intraperitoneal injection. For insulin
tolerance tests, nonfasting mice were given insulin (0.75 IU/kg) (Eli Lilly,
Indianapolis, IN) by intraperitoneal injection. Blood glucose was measured
using Glucometer Elite XL (Bayer).
Hyperinsulinemic-euglycemic clamp studies. Hyperinsulinemic-euglycemic
clamps were performed by a modification of a described procedure (15).
Briefly, right jugular vein of killed mice (80–10 mg/kg ketamine-xylazine i.p.)
was catheterized with heparin-coated MRE-025 tubing (Becton Dickinson,
Franklin Lakes, NJ). Animals were allowed to recover for 1–2 days. Insulin (10
mU  kg1  min1) containing 0.3% BSA was infused at the rate of 1 l/min
using a syringe pump (HA11D, Harvard apparatus, Holliston, MA). At 5-min
intervals, 2 l of tail vein blood was drawn to measure blood glucose.
Dextrose (25%) was infused at a rate sufficient to maintain blood glucose of
140 mg/dl. Average glucose infusion rate (GIR) was measured over the final 30
min of the 2-h clamp. Insulin was measured in blood samples from the last
three collections.
Muscle [3H]-2-deoxyglucose uptake. Muscle uptake of the metabolically
inert glucose analog, [3H]-2-deoxyglucose (DOG), was performed in mice at 30
min before the end of 2-h hyperinsulinemic-euglycemic clamp experiments,
with modification to methods described previously (15). Briefly, DOG (30 Ci)
was administered intraperitoneally, and mouse hind-limb muscles were har-
vested, denatured, and the eluates were quantified using liquid scintillation
analyzer (TriCarb 3100TR, PerkinElmer, Shelton, CT). The rate of glucose
uptake was calculated by dividing the muscle DOG uptake over a 30-min
interval (cpm  kg1  min1) by the mean blood glucose–specific activity
(glucose cpm/mg).
Histology. Liver tissues were embedded in OCT. Serial 10 m-thick cytosec-
tions were prepared at the Rodent Histopathology Core at Harvard Medical
School (Boston, MA) and were stained with Oil Red O and hematoxylin-eosin.
Intrahepatic lipid measurements. Livers were lyophilized using Freeze Dry
System (Freezone, Labconco, Fort Scott, KS) to obtain liver dry weight. Liver
lipids were extracted by the Folch method (16). Liver cholesterol and
triglycerides were measured using Infinity Cholesterol (Thermo Electron,
Pittsburgh, PA) and T2449 Triglyceride Reagent (Sigma Aldrich, St. Louis,
MO), respectively.
Mitochondrial fatty acid -oxidation measurement. Fresh liver tissue
was homogenized in 250 mmol/l sucrose, 0.1 mmol/l EDTA, 50 mmol/l KCl, and
10 mmol/l HEPES (pH 7.4) and centrifuged at 1,000  g for 5 min. The
supernatant was centrifuged at 10,000  g for 15 min, and pellets were
dissolved in 50 mmol/l KCl, 70 mmol/l sucrose, 3.6 mmol/l MgCl2, 7.2 mmol/l
K2HPO4, and 36 mmol/l Tris-HCl (pH 7.4). Protein concentrations were
measured using Bradford reagent (Bio-Rad, Hercules, CA). In addition, 5
Ci/ml [3H]-palmitate was incubated with 1 mg of mitochondria in preincu-
bation buffer with 2 mmol/l KCN at room temperature for 30 min. Reaction
was subsequently incubated for 60 min in 5% perchloric acid, and supernatants
were counted in a liquid scintillation counter.
Hepatic VLDL (apoB100) secretion. VLDL secretion rate was measured by
modification of a previously described method (17). Briefly, fasted mice were
injected with Triton WR 1339 (500 mg/kg; Sigma Chemical, St. Louis, MO) via
tail vein to block lipolysis. Blood samples were collected at baseline, 90 min
and 180 min after injection. Plasma apoB100 was determined by Western blot
analysis using anti-apoB antibody (Santa Cruz Biotechnology, Santa Cruz,
CA). Hepatic VLDL secretion was calculated by the percentage increase in
plasma apoB100 from baseline.
Western blot analysis. One microliter of plasma per lane was analyzed after
treatment with sample buffer containing SDS and -mercaptoethanol, fol-
lowed by separation in 4–15% Tris-HCl gradient gel (Bio-Rad, Hercules, CA).
Liver and muscle tissue samples were extracted and processed as previously
described (12). All primary, except anti–fatty acid synthase antibodies (Cell
Signaling Technology, Danvers, MA), and secondary antibodies were pur-
chased from Santa Cruz Biotechnnology.
Real-time Q-PCR. Total RNA was extracted from frozen liver using RNeasy
mini kit (Qiagen, Valencia, CA). For reverse transcription, 1 g of the total
RNA was converted to first-strand complementary DNA in 20 l reactions
using AffinityScript Q-PCR cDNA Synthesis Kit (Agilent Technologies, La Jolla,
CA), which was subsequently diluted five times. For PCR sample preparation,
5 l of cDNA was mixed in 20 l reaction volume with 10 mol/l primer and
SYBR master enzyme mix (SABiosciences, Frederick, MD). The reaction was
initiated at 94°C for 10 min, followed by 40 cycles through 94oC  15 s and
60oC  1 min. All reactions were performed in duplicate. All CT values were
in the range of 20–30 cycles. Amplification curves were analyzed using SDS
1.9.1 software (Applied Biosystems, Foster City, CA). Hprt1 controls provided
relative gene expression levels. Refer to supplementary Table 1 (available in
an online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-0349/DC1) for primers.
Statistical analysis. Experimental results are shown as means 	 SE. The
mean values from two independent groups were compared by using Student’s
t test for independent samples. Differences among multiple groups were
assessed using ANOVA models. If ANOVA revealed a significant overall effect,
then individual groups were compared by using Tukey’s procedure. Longitu-
dinal data from multiple groups of animals were compared by using repeated
measures ANOVA, with a time-in-treatment factor and a treatment group
factor. All statistical tests were one-tailed and P 
 0.05 were considered
significant.
RESULTS
Mstn deletion retards whole body, visceral, and sub-
cutaneous fat accumulation. Ldlr/ mice with varying
Mstn genotypes, wild type (Mstn//Ldlr/), heterozy-
gous deletion (Mstn//Ldlr/), and homozygous dele-
tion (Mstn//Ldlr/), were fed HFD for 11–12 weeks.
Mstn//Ldlr/ controls demonstrated substantial gains
in body weight, whole body fat mass (measured by NMR),
and visceral and subcutaneous fat mass (measured by
micro-CT scan). In contrast, Mstn//Ldlr/ mice re-
sisted weight gain and accumulation of whole body and
visceral fat mass in response to HFD (Fig. 1A and B,
supplementary Fig. 1A and B, available in an online
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appendix). In agreement with the in vivo NMR data, the
wet weights of the major fat depots (inguinal, epididymal,
perirenal, as well as the interscapular brown fat) were
significantly lower in the Mstn//Ldlr/ mice, as com-
pared with wild-type, Mstn//Ldlr/, and Mstn//
Ldlr/ mice (Fig. 1C). Thus, Mstn//Ldlr/ mice are
resistant to fat accumulation in all fat depots including the
visceral and subcutaneous fat depot.
As expected, theMstn//Ldlr/mice had significantly
greater skeletal muscle mass, as indicated by the twofold
higher mass of the gastrocnemius and the quadriceps
femoris muscle groups (Fig. 1D; supplementary Fig. 1C
and D, available in an online appendix) than in the
Mstn//Ldlr/ controls. Throughout the course of HFD,
Mstn//Ldlr/ mice maintained significantly greater
lean mass (assessed by NMR) compared with other geno-
type groups (Fig. 1D; supplementary Fig. 1C, available in
an online appendix). The soleus muscle, a primarily oxi-
dative muscle type, was not statistically significantly af-
fected by Mstn disruption (supplementary Fig. 1E,
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FIG. 1. Effects of Mstn disruption on body fat accumulation in Ldlr/ mice. A: Representative gross appearance (top panel) and micro-CT image
of visceral and subcutaneous fat (bottom panel) of mice after 12 weeks of HFD (HF-diet). c, cecum; vf, visceral fat, sf, subcutaneous fat. B: NMR
analysis of total fat at baseline (time 0) and after 5 and 10 weeks of HFD. Mstn//Ldlr/, ; Mstn//Ldlr/, E; Mstn/Ldlr/, Œ;
Mstn/Ldlr/, F. C: Inguinal, epididymal, perirenal, and intrascapular brown fat weights of mice after 12 weeks of HFD. D: Representative gross
appearance of hind-limb muscles (left panel) and quadriceps muscle weights (right panel) of mice after 12 weeks of HFD. /,
Mstn//Ldlr/. /, Mstn//Ldlr/. /, Mstn/Ldlr/. /, Mstn//Ldlr/. Data are expressed as means  SE (n  11–21). **P <
0.01 compared with all other genotypes. (A high-quality digital representation of this figure is available in the online issue.)
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available in an online appendix). Ldlr/ mice with het-
erozygous deletion of Mstn only displayed modest in-
crease in muscle mass but have similar fat mass
accumulation compared with Mstn//Ldlr/ controls
when fed HFD.
Despite the remarkable effects ofMstn deletion on body
composition, neither the energy intake nor energy expen-
diture differed significantly among the various groups on
normal rodent diet (data not shown) or on HFD (supple-
mentary Fig. 2A, available in an online appendix). Ambu-
latory activity levels on HFD were assessed by infrared
beam interruption, and notably, the horizontal ambulatory
activity of Mstn//Ldlr/ double-knockout group was
38% lower than that of controls (supplementary Fig. 2B,
available in an online appendix). However, despite this
reduction in activity, analysis of whole body O2 consump-
tion (VO2) showed that energy expenditure was similar
between the two groups (supplementary Fig. 2C, available
in an online appendix). If the data were expressed as a
function of lean mass weight, Mstn//Ldlr/ actually
had lower VO2 rate (13%) compared with controls. Further-
more, the respiratory exchange ratios were 0.85 in
Ldlr/ mice with or without Mstn disruption, reflecting
mixed utilization of carbohydrate and fatty acid oxidation
in both animal groups (supplementary Fig. 2D, available in
an online appendix). Thus, the resistance to fat accumu-
lation in Mstn//Ldlr/ mice cannot be explained based
on reduced food intake, increased whole-body O2 con-
sumption, or preference for fuel disposition.
Mstn deletion reduces diet-induced atherogenesis in
Ldlr/ mice. To determine whether deletion of Mstn
mitigates the development of vascular lesions, we first
used in vivo MRA to evaluate lumen occlusion of the
brachiocephalic artery, one of the most lesion-prone sites
(Fig. 2A). After 8 weeks of HFD, Mstn//Ldlr/ mice
showed reduced lumen size and increased asymmetry
(Fig. 2B–D); in contrast, brachiocephalic arterial lumen of
Mstn//Ldlr/ maintained patency without significant
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FIG. 2. Effects of Mstn disruption on atherogenesis progression in Ldlr/ mice. A: Representative MRA of aortic arch and its major branches.
BCA, brachiocephalic artery. B: Cross-sectional image of BCA. C and D: Symmetry coefficient (ratio of the largest to the smallest diameter) (C),
and cross-sectional area (D) of BCA lumen (n  4). E: Oil Red O staining of atherosclerotic lesions in aortic root at the level of the aortic valves
(top panel). Magnification 40. Gross aortic arch and branches (bottom panel) (n  9–20). F and G: Sudan IV staining of en face aortas (F) and
quantitative analyses of atherosclerotic lesion areas (percent of total aortic surface area) (G) (n  9–20). /, Mstn//Ldlr/. /,
Mstn//Ldlr/. /, Mstn/Ldlr/. /, Mstn//Ldlr/. Data are expressed as means  SE (n  11–21). **P < 0.05. **P < 0.01. (A
high-quality digital representation of this figure is available in the online issue.)
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occlusion, as indicated by greater symmetry and signifi-
cantly larger (1.7-fold) lumen area (Fig. 2C and D).
After 12 weeks of HFD, animals were killed and aortas
were dissected. Mstn//Ldlr/ mice developed large
plaques that were eccentric (partial circumference of
arterial wall) and dispersed along the arch and in the
descending aorta (Fig. 2E). Staining with Oil Red O
revealed that the lesions were lipid rich (Fig. 2E). Analysis
of the en face aorta demonstrated that atheromatous
lesion area inMstn//Ldlr/mice was 41% lower than in
Mstn//Ldlr/ controls (Fig. 2F and G). In correlation
with the similar fat mass accumulation (Fig. 1B and C),
Mstn//Ldlr/ mice had similar lesion area compared
with Mstn//Ldlr/ controls (Fig. 2G), suggesting that
heterozygous deletion ofMstn is not sufficient in providing
protection against either fat accumulation or atherogene-
sis. The negative control, Mstn//Ldlr/ mice group,
had no detectable lesions. Thus, Ldlr/ mice with Mstn
deletion were protected against the development/progres-
sion of atheromatous lesions.
We next investigated the mechanisms by which disrup-
tion of Mstn retards atherogenesis progression. As circu-
lating lipids are important contributors to atherogenesis,
we determined the changes in plasma lipids and
lipoproteins.
Mstn deletion in Ldlr/ mice attenuates proathero-
genic dyslipidemia. Even before HFD induction, Mstn//
Ldlr/ mice had significantly lower plasma triglycerides,
free fatty acids (FFA), and total cholesterol levels com-
pared withMstn//Ldlr/mice (Fig. 3A). After 10 weeks
of HFD, Mstn//Ldlr/ controls displayed marked in-
crease in plasma triglycerides (3.0-fold), FFA (2.3-fold),
and cholesterol (3.8-fold) levels compared with baseline;
the changes in plasma lipids were significantly greater
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FIG. 3. Atherogenic lipid profile in Ldlr/ mice with Mstn deletion. A and B: Fasting plasma FFA, triglycerides, and cholesterol levels of mice
at baseline (A) and after 10 weeks of HFD (HF-diet) (B). C and D: Lipoprotein profile in Mstn//Ldlr/ (E) and Mstn//Ldlr/ (F) mice after
11 weeks of HFD. Data are presented as average cholesterol (C) and triglycerides (D) distribution for each group. E: Plasma apoA1- and
apoB100-containing lipoprotein particles before and after induction of HFD. The graphs demonstrate the quantification of each molecule,
displayed as apoB100/apoA1 ratio. Averages were taken from four different gels. Blood was drawn from mice after 10 weeks of HFD. /,
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P. TU AND ASSOCIATES
DIABETES, VOL. 58, AUGUST 2009 1743
than those observed in Mstn//Ldlr/ mice after HFD.
Plasma triglycerides, FFA, and cholesterol levels after
HFD were significantly lower in Mstn//Ldlr/ than in
Mstn//Ldlr/ controls (Fig. 3B), suggesting that
Mstn deletion protects against the development of
proatherogenic dyslipidemia in Ldlr/ mice fed HFD.
We fractionated plasma lipoproteins by using fast-phase
liquid chromatography. Plasma total cholesterol, VLDL-
cholesterol, and LDL cholesterol levels were lower in
Mstn//Ldlr/ mice than in Mstn//Ldlr/ controls
(Fig. 3C). Triglyceride contents of VLDL (VLDL-TG) and
LDL fractions (LDL-TG) were also significantly lower in
Mstn//Ldlr/ mice than controls (Fig. 3D).
ApoB is an important predictor of cardiovascular risk;
some patients with elevated apoB100 levels are at in-
creased risk of cardiovascular disease despite having
target cholesterol levels (18,19). We analyzed the plasma
apoB100 contents in our mice. Western blot analysis of
plasma samples of Mstn//Ldlr/ mice showed a signif-
icant increase in apoB100 after 11 weeks of HFD, and this
diet effect was markedly attenuated in Mstn//Ldlr/
mice (Fig. 3E). We also measured apoA1, the scaffold
protein for HDL. The ratio of apoB100 to apoA1, which is
stoichiometrically related to the ratio of non-HDL to HDL
particles, was lower in Mstn//Ldlr/ mice compared
with controls (Fig. 3E), suggesting a more favorable li-
poprotein profile in Mstn//Ldlr/ mice.
Mstn//Ldlr/ mice have greater insulin-mediated
glucose disposal. Diet-induced obesity is strongly asso-
ciated with deterioration of insulin sensitivity, clinically
evidenced by increased circulating insulin, glucose, tri-
glycerides, and FFA (20). Insulin also serves as an impor-
tant regulator of adipose lipolysis and hepatic VLDL
production. Dysregulation of these metabolic functions of
insulin could contribute to hyperlipidemia and accelerate
atherosclerosis in mice fed with HFD (21,22). Accordingly,
we assessed the effect of Mstn deletion on insulin sensi-
tivity in Ldlr/ mice.
In addition to having lower plasma triglycerides, FFA,
VLDL, and apoB concentrations, Mstn//Ldlr/ mice
also had significantly lower fasting blood glucose and
insulin levels. These data suggested that Mstn//Ldlr/
mice were more insulin sensitive than Mstn//Ldlr/
controls even when fed HFD (Fig. 4A–C). Plasma insulin-
to-glucagon ratio was also significantly lower (30% in
Mstn//Ldlr/mice). Glucose tolerance test did not reveal
significant differences between rate of glucose disposal
(supplementary Fig. 3A, available in an online appendix),
but this could be because of the compensatory increase in
fasting insulin in Mstn//Ldlr/ (Fig. 4B). When mice
were injected with a fixed dose of insulin during insulin
tolerance tests, Mstn//Ldlr/ mice maintained signifi-
cantly lower blood glucose than their Mstn//Ldlr/
littermates (supplementary Fig. 3B, available in an online
appendix). Furthermore, Ldlr/ mice with Mstn deletion
had significantly lower phosphoenolpyruvate carboxyki-
nase one (Pepck) expression (supplementary Fig. 3C,
available in an online appendix), the rate-limiting hepatic
gluconeogenic enzyme (23), consistent with improved
insulin sensitivity.
To confirm our findings of improved insulin sensitivity
in Mstn//Ldlr/ mice, we performed hyperinsulinemia-
euglycemic clamp studies, the accepted gold standard for
assessing insulin sensitivity (24). Mstn//Ldlr/ re-
quired significantly higher GIR to maintain euglycemia
(Fig. 4D and E) than in controls. These data demonstrate
thatMstn deletion improves whole body insulin sensitivity
through the enhancement of insulin-stimulated glucose
disposal in peripheral tissues. It is possible that the
increased GIR is simply because of greater muscle mass
and the resulting increase in metabolic demand of the
double-knockout mice. To explore this further, we mea-
sured the rates of [3H]-2-deoxyglucose uptake in skeletal
muscle during the clamp procedure. In the Mstn//
Ldlr/ mice, glucose uptake in quadriceps muscle was
significantly higher compared with that of the Mstn//
Ldlr/ controls (Fig. 4F) in a similar hyperinsulinemic
state (Fig. 4G). Furthermore, phosphorylation of serine-
473 in Akt, the pleiotropic kinase essential for many
metabolic actions of insulin, was significantly higher in
muscle tissues of Mstn//Ldlr/ mice compared with
that of the controls. Phosphorylation of serine-21/9 in
GSK3, one of Akt substrates, was also significantly higher,
providing further evidence of improved insulin action in
the skeletal muscle (Fig. 4H). Together, these data dem-
onstrate that HFD induces an insulin-resistant state in
Mstn//Ldlr/ mice and that disruption of Mstn pre-
vents the development of insulin resistance, as consistent
with other reports (9,10).
Mstn//Ldlr/ are protected against hepatic ste-
atosis and have higher hepatic fatty acid -oxidation
and lower VLDL secretion rates. The liver plays a
leading role in systemic lipid homeostasis (25). In re-
sponse to HFD feeding, the livers ofMstn//Ldlr/mice
displayed substantial fat accumulation (Fig. 5A). In con-
trast, Mstn//Ldlr/ mice had significantly lower he-
patic triglyceride content, as well as total wet and dry liver
weights (Fig. 5A; supplementary Fig. 4A, available in an
online appendix). This protection against diet-induced
hepatic fat infiltration in Mstn//Ldlr/ mice was asso-
ciated with significant reduction in plasma adipose-
derived FFA (Fig. 3A), glucose, and insulin (Fig. 4A and B),
as well as with diminished expression of lipogenic master
gene, sterol regulatory element–binding transcription fac-
tor 1 (Srebf1), and its key downstream target, fatty acid
synthase mRNA and protein (Fig. 5B–D).
Hepatic fatty acid -oxidation has been shown to pre-
vent diet-induced obesity, fatty liver, and hyperlipidemia
(26). In our Mstn//Ldlr/ mice model, hepatic fatty
acid -oxidation rates in isolated hepatic mitochondrion
were significantly greater (1.7-fold; supplementary Fig. 4B,
available in an online appendix) than those from controls.
In addition, we have previously shown that Mstn deletion
resulted in a 25% increase of liver mitochondrial DNA
(unpublished data), implying that these mice have greater
mitochondrial oxidation capacity. Plasma level of the
ketone body -hydroxybutyrate, an indirect marker of
hepatic fatty acid -oxidation, was also significantly higher
inMstn//Ldlr/ (supplementary Fig. 4C, available in an
online appendix) than in controls.
Decreased hepatic triglycerides in Mstn//Ldlr/
mice was associated with reduced secretion of hepatic
triglycerides (23%) and VLDL (Fig. 5E). Suppression of
hepatic fat accumulation in Mstn//Ldlr/ mice was
associated with enhanced insulin action in the liver. The
mRNA expression levels of insulin receptor substrate
(Irs)1 and Irs2, two key players in the regulation of
hepatic insulin signaling (27), were significantly higher
in Mstn//Ldlr/ mice compared with Mstn//
Ldlr/ controls (supplementary Fig. 4D, available in an
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online appendix). Western blot analyses also showed
significantly higher Akt and GSK phosphoryation in
isolated liver tissues of Mstn//Ldlr/ mice (Fig. 5F).
As emerging data suggest a causative role of intracellu-
lar hepatic triglyceride accumulation in the pathogene-
sis of hepatic insulin resistance and hypersecretion of
VLDL (23,28–30), these findings provide a mechanistic
link between the protective effects of Mstn deletion on
obesity, insulin resistance, and atherosclerosis (supple-
mentary Fig. 5, available in an online appendix).
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DISCUSSION
In this report, we provide the evidence that Mstn disrup-
tion in Ldlr/ mice reduces the development of
proatherogenic dysipidemia and atherogenesis progres-
sion. The Mstn//Ldlr/ mice had lower plasma triglyc-
erides, FFA, and non-HDL cholesterol than controls.
Mstn//Ldlr/ mice also had lower hepatic VLDL secre-
tion rates. Although we cannot exclude direct actions of
myostatin on the blood vessel wall, it is likely that the
more favorable plasma lipid profile was the key contribu-
tor to reduced atherogenesis progression observed in
Mstn//Ldlr/ mice.
Mstn deletion prevented the development of diet-
induced insulin resistance in Ldlr/ mice. Hyperinsuline-
mic-euglycemic clamp studies revealed that Mstn//
Ldlr/ mice had significantly higher peripheral glucose
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disposal rates. Furthermore, decreased circulating insulin
as well as decreased glucose and adipose-derived FFA
influx to the liver of the double-knockout mice may
contribute to the protection against hepatic lipogenesis
and hepatic insulin resistance (23,25,28).
The mechanisms by which Mstn deletion improves
insulin sensitivity are not fully understood. Mstn//
Ldlr/ mice remained remarkably lean and resisted fat
accumulation even when fed HFD for 12 weeks. Myostatin
may exert complex effects on adipogenic differentiation
(31,32). In addition, it is possible that acquisition of
hypermuscularity by itself could lead to leanness (11).
Indeed, mice with increased muscle oxidation, such as
those overexpressing IGF-1 (33) or Akt-1 (11) in skeletal
muscles, have little fat deposition. In our myostatin-
deficient model, the marked hypertrophy of glycolytic
skeletal muscle was associated with increased glucose
uptake, lower blood glucose levels, and consequently
lower circulating levels of insulin (11).
Increased hepatic fatty acid -oxidation (FAO) and
mitochondrial biogenesis with Mstn disruption may pre-
vent the development of hepatic steatosis that was ob-
served in Mstn//Ldlr/ controls (25,26). Consistent
with the higher FAO rates, Mstn//Ldlr/ mice had
higher ketone body production than controls. Improved
insulin sensitivity might be expected to suppress FAO and
lower ketone body production. However, insulin only
effectively suppresses FAO in tissues, primarily muscle
and fat, where glucose uptake is tightly regulated by
insulin. Because hepatic glucose uptake is not regulated by
insulin (34), improved insulin sensitivity in the Mstn//
Ldlr/ mice does not pose limitation on liver FAO as it
does in the skeletal muscle. This phenomenon has also
been observed by others (11,35). Our data suggest that the
increased ketone body production in the double-knockout
mice may be a result of physiological adaptation to limited
adipose tissue storage for dietary fats from HFD.
Myostatin may also indirectly affect cardiometabolic
risk by its effects on myokine secretion by the skeletal
muscle. Similar to systemic loss of Mstn, inhibition of
myostatin signaling exclusively in the skeletal muscle was
sufficient to resist diet-induced obesity and insulin resis-
tance (10). Myokines, such as interleukin-6, can alter
metabolic states (36). Other myokines, such as fibroblast
growth factor-21 (Fgf-21) and follistatin like-1 (Fstl-1),
may also have salutary effects on fat accumulation and
insulin sensitivity (37,38).
In summary, we have demonstrated here that Mstn
deletion has beneficial cardiometabolic effects in an ani-
mal model of atherosclerosis. Mstn//Ldlr/ mice are
partially protected against not only fat accumulation and
insulin resistance but also the development of proathero-
genic dyslipidemia and atherosclerosis. These proof-of-
concept studies raise the possibility that myostatin
inhibitors may be useful agents for the prevention or
treatment of atherosclerosis. Importantly, administration
of myostatin inhibitors to humans have demonstrated
specificity, safety, and effectiveness in increasing muscle
mass and decreasing fat mass (39). To the extent that loss
of skeletal muscle mass, adiposity, and atherogenesis
occur contemporaneously during aging and in many
chronic illnesses, new classes of promyogenic drugs, such
as myostatin inhibitors, that increase skeletal muscle mass
and retard fat accumulation are particularly attractive
against these cardiometabolic disorders.
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